| Autor: |
Sharpe RH; Extended Care and Primary Care Services, Dorn VA Medical Center, 6439 Garner's Ferry Road, Columbia, SC 29209, USA. Rachel.Sharpe@med.va.gov, Voris JC |
| Jazyk: |
angličtina |
| Zdroj: |
Expert review of neurotherapeutics [Expert Rev Neurother] 2002 Sep; Vol. 2 (5), pp. 617-23. |
| DOI: |
10.1586/14737175.2.5.617 |
| Abstrakt: |
Post-traumatic stress disorder occurs in patients who have undergone a traumatic experience and manifests itself through a cluster of symptoms, including re-experiencing, avoidance and hyperarousal. Post-traumatic stress disorder is commonly found among veterans of war and victims of sexual trauma, natural disasters and accidents. Nefazodone is a medication that has an FDA-approved indication for treating depression. Nefazodone has also been reported to be efficacious in treating post-traumatic stress disorder. Despite recent reports of hepatotoxicity, when used appropriately, nefazodone is generally as well-tolerated as the medications currently FDA-indicated for post-traumatic stress disorder, the selective serotonin reuptake inhibitors. Through its mechanism inhibiting neuronal uptake of serotonin and norepinephrine and as a potent postsynaptic serotonergic antagonist, nefazodone has proven to be effective in treating post-traumatic stress disorder in several open-label trials. The results of such trials warrant its study in larger, double-blind, placebo-controlled clinical trials. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
